| 1 | Why COVID-19 trials should be blinded (as any other one) (10.17267/2675-021xevidence.v2i1.2841) | Abstract References ORCID | 45.15 | 3 |
| 2 | Better understanding of ‘don’t confuse absence of evidence w… (10.17267/2675-021xevidence.v1i2.2348) | Abstract References ORCID | 35.78 | 2 |
| 3 | Hydroxychloroquine and chloroquine for COVID-19 infection. R… (10.17267/2675-021xevidence.v2i1.2843) | References ORCID | 34.95 | 4 |
| 4 | Physicians’ preference towards the non-evidence based hydrox… (10.17267/2675-021xevidence.v2i1.3014) | References ORCID | 30.10 | 3 |
| 5 | From SARS to COVID-19: lessons we should have learned (but w… (10.17267/2675-021xevidence.2021.e3837) | References ORCID | 23.86 | 2 |
| 6 | Evidence-based practice questionnaire for physical therapist… (10.17267/2675-021xevidence.v1i2.2575) | References ORCID | 23.86 | 2 |
| 7 | An immunization program against the COVID-19 infodemic (10.17267/2675-021xevidence.v2i1.3124) | Abstract References | 23.86 | 2 |
| 8 | Artificial intelligence in health and science: an introspect… (10.17267/2675-021xevidence.2023.e5236) | References | 17.47 | 4 |
| 9 | Protocolo de estudo para avaliar função sexual nas mulheres… (10.17267/2675-021xevidence.2021.e3396) | References ORCID | 15.05 | 1 |
| 10 | Slow Medicine and Choosing Wisely: a synergistic alliance (10.17267/2675-021xevidence.2022.e4222) | References | 15.05 | 3 |
| 11 | Prevalence of Diabetes Mellitus among individuals with chron… (10.17267/2675-021xevidence.2023.e4060) | References | 15.05 | 3 |
| 12 | Knowledge and attitudes of entry-level and final-level physi… (10.17267/2675-021xevidence.v1i1.1983) | References ORCID | 15.05 | 1 |
| 13 | On presenting Evidence and unboxing science (10.17267/2675-021xevidence.v1i1.2362) | Abstract References | 15.05 | 1 |
| 14 | Hydroxychloroquine for the treatment of COVID-19: an approac… (10.17267/2675-021xevidence.v2i1.2890) | Abstract References | 15.05 | 1 |
| 15 | Using resources wisely in the COVID-19 pandemic: an internat… (10.17267/2675-021xevidence.v2i1.2898) | References ORCID | 15.05 | 1 |
| 16 | The costly hydroxychloroquine battle in Brazil (10.17267/2675-021xevidence.v2i1.3054) | Abstract References | 15.05 | 1 |
| 17 | Potential treatments for COVID-19 are not parachutes – avoi… (10.17267/2675-021xevidence.v2i1.3058) | Abstract References | 15.05 | 1 |
| 18 | The immediate effect of transcranial direct current stimulat… (10.17267/2675-021xevidence.v2i2.2926) | References ORCID | 15.05 | 1 |
| 19 | Evidence, Experts and Systematic Reviews. Has COVID-19 chang… (10.17267/2675-021xevidence.v2i2.3632) | Abstract References | 15.05 | 1 |
| 20 | Are some physicians afraid of the COVID-19 vaccines? A tale… (10.17267/2675-021xevidence.v2i2.3813) | Abstract References | 15.05 | 1 |
| 21 | A literature review on COVID-19 [coronavirus] research speci… (10.17267/2675-021xevidence.2022.e3846) | References | 11.93 | 2 |
| 22 | Methodologic quality and risk-of-bias in systematic reviews… (10.17267/2675-021xevidence.2022.e4067) | References | 11.93 | 2 |
| 23 | A relação entre linguagem e práticas pseudocientíficas (10.17267/2675-021xevidence.2023.e4970) | References | 11.93 | 2 |
| 24 | Os Princípios de Hong Kong e sua importância para o ecossist… (10.17267/2675-021xevidence.v2i2.3247) | References | 11.93 | 2 |
| 25 | The impact of personal pseudoscientific beliefs in the pursu… (10.17267/2675-021xevidence.2021.e3516) | References | 7.53 | 1 |
| 26 | Iniciativa Choosing Wisely Brasil para a Fisioterapia na Saú… (10.17267/2675-021xevidence.2022.e4354) | References | 7.53 | 1 |
| 27 | Histomorphometric evaluation of skin wounds in rats submitte… (10.17267/2675-021xevidence.2023.e4105) | References | 7.53 | 1 |
| 28 | A brief history of evidence-based medicine (10.17267/2675-021xevidence.v1i2.2485) | References | 7.53 | 1 |
| 29 | HPV vaccines for prevention of cervical pre-cancer in adoles… (10.17267/2675-021xevidence.v1i2.2510) | References | 7.53 | 1 |
| 30 | O aumento da má conduta científica nas pesquisas da área de… (10.17267/2675-021xevidence.2021.e3389) | Abstract References ORCID | 0.00 | 0 |
| 31 | Bias and unclear outcomes in clinical trials of diabetic ret… (10.17267/2675-021xevidence.2021.e3415) | References ORCID | 0.00 | 0 |
| 32 | Análise epidemiológica de 9.897 óbitos por COVID-19 no perío… (10.17267/2675-021xevidence.2021.e3447) | References | 0.00 | 0 |
| 33 | The rhetoric of preprints (10.17267/2675-021xevidence.2021.e3732) | Abstract References ORCID | 0.00 | 0 |
| 34 | Misoprostol compared to oxytocin for postpartum hemorrhage (10.17267/2675-021xevidence.2021.e3733) | Abstract References | 0.00 | 0 |
| 35 | Associação entre o uso excessivo de álcool e fibrilação atri… (10.17267/2675-021xevidence.2021.e3748) | Abstract References | 0.00 | 0 |
| 36 | Methylprednisolone versus dexamethasone for Covid-19 patient… (10.17267/2675-021xevidence.2021.e3814) | Abstract References ORCID | 0.00 | 0 |
| 37 | Protocolo de estudo para comparar a influência do uso de con… (10.17267/2675-021xevidence.2022.e3744) | References | 0.00 | 0 |
| 38 | Study protocol for thermographic analysis of the nasolabial… (10.17267/2675-021xevidence.2022.e3754) | References | 0.00 | 0 |
| 39 | Risk of bias analysis in diabetic retinopathy randomized cli… (10.17267/2675-021xevidence.2022.e3791) | References | 0.00 | 0 |
| 40 | Overuse: medical novelty or age-old phenomenon? (10.17267/2675-021xevidence.2022.e3792) | References | 0.00 | 0 |
| 41 | Revisão externa das Diretrizes da SBC segundo a ferramenta A… (10.17267/2675-021xevidence.2022.e3930) | References | 0.00 | 0 |
| 42 | Protocolo da pesquisa: impacto da presença de úlcera péptica… (10.17267/2675-021xevidence.2022.e3984) | References | 0.00 | 0 |
| 43 | Covid-19 research evidence: An international survey explorin… (10.17267/2675-021xevidence.2022.e4010) | References | 0.00 | 0 |
| 44 | Platelet-Rich Fibrin for treating temporomandibular disorder… (10.17267/2675-021xevidence.2022.e4165) | References | 0.00 | 0 |
| 45 | Effect of neuromodulation on pain and functional mobility in… (10.17267/2675-021xevidence.2022.e4193) | References | 0.00 | 0 |
| 46 | Extended infusion of cephalosporins, penicillins and carbape… (10.17267/2675-021xevidence.2022.e4605) | References | 0.00 | 0 |
| 47 | More is exponentially less: marginal utility in critical car… (10.17267/2675-021xevidence.2022.e4722) | References | 0.00 | 0 |
| 48 | Protocol for evaluating the in vitro effect of violet light-… (10.17267/2675-021xevidence.2022.e4736) | References | 0.00 | 0 |
| 49 | Perceived impact of a one-week journalology training course… (10.17267/2675-021xevidence.2023.e5107) | References | 0.00 | 0 |
| 50 | Quality of reporting in abstracts of clinical trials using p… (10.17267/2675-021xevidence.2023.e5173) | References | 0.00 | 0 |
| 51 | The temporality of economic decisions applied to clinical re… (10.17267/2675-021xevidence.2024.e5435) | References | 0.00 | 0 |
| 52 | Irritable Bowel Syndrome (IBS) and medical misinformation: l… (10.17267/2675-021xevidence.2024.e5444) | | 0.00 | 3 |
| 53 | Mandating patient and public involvement in research: is it… (10.17267/2675-021xevidence.2024.e5681) | | 0.00 | 0 |
| 54 | In the footsteps of giants: a tale of legacy and discovery i… (10.17267/2675-021xevidence.2024.e5876) | Abstract | 0.00 | 0 |
| 55 | When math legitimizes knowledge: a step by step approach to… (10.17267/2675-021xevidence.2024.e5903) | | 0.00 | 0 |
| 56 | The distinctions and the value of physician-scientists: a ca… (10.17267/2675-021xevidence.2025.e5954) | | 0.00 | 0 |
| 57 | The interplay of belief and skepticism in advancing science… (10.17267/2675-021xevidence.2025.e5962) | | 0.00 | 0 |
| 58 | Could performance bias have influenced the prevention of pre… (10.17267/2675-021xevidence.2025.e6005) | References | 0.00 | 0 |
| 59 | Givers and takers in science: thriving through genuine colla… (10.17267/2675-021xevidence.2025.e6098) | | 0.00 | 0 |
| 60 | How to train your future leader in medical science (10.17267/2675-021xevidence.2025.e6305) | References | 0.00 | 0 |
| 61 | Are massage parameters well reported in clinical trials? A s… (10.17267/2675-021xevidence.v1i1.1948) | References | 0.00 | 0 |
| 62 | The contribution of Douglas Altman’s research to the EVIDENC… (10.17267/2675-021xevidence.v1i1.2007) | Abstract References | 0.00 | 0 |
| 63 | Empaglifozin cardiovascular benefit: can we separate fact fr… (10.17267/2675-021xevidence.v1i1.2095) | Abstract References ORCID | 0.00 | 0 |
| 64 | Composite outcomes – the devil is in the details (10.17267/2675-021xevidence.v1i1.2149) | Abstract References | 0.00 | 0 |
| 65 | O fim do jogo para Pantoprazol na UTI? Não tão rápido… (10.17267/2675-021xevidence.v1i1.2199) | Abstract References | 0.00 | 0 |
| 66 | A era da Fisioterapia Baseada em Evidências: o despertar de… (10.17267/2675-021xevidence.v1i1.2205) | Abstract References ORCID | 0.00 | 0 |
| 67 | Transparency in Reporting Results From Randomized Clinical T… (10.17267/2675-021xevidence.v1i1.2254) | Abstract References ORCID | 0.00 | 0 |
| 68 | Unconscious BIAS: we are more biased than we think! (10.17267/2675-021xevidence.v1i1.2262) | Abstract References | 0.00 | 0 |
| 69 | International Guidelines - Effects causing different recomme… (10.17267/2675-021xevidence.v1i1.2264) | Abstract References ORCID | 0.00 | 0 |
| 70 | Why Unbox Evidence-based Medicine? (10.17267/2675-021xevidence.v1i1.2364) | Abstract References ORCID | 0.00 | 0 |
| 71 | Science must speak truth to power (10.17267/2675-021xevidence.v1i1.2366) | Abstract References | 0.00 | 0 |
| 72 | Masthead (10.17267/2675-021xevidence.v1i1.2423) | Abstract References ORCID | 0.00 | 0 |
| 73 | Characteristics of systematic reviews published in dentistry… (10.17267/2675-021xevidence.v1i2.2506) | References ORCID | 0.00 | 0 |
| 74 | The value of uncertainty: the Zika and Microcefalia link (10.17267/2675-021xevidence.v1i2.2541) | References | 0.00 | 0 |
| 75 | TheNNT.com: the concept, the mission, and the history (10.17267/2675-021xevidence.v1i2.2554) | Abstract References ORCID | 0.00 | 0 |
| 76 | In praise of “Our stubborn quest for diagnostic certainty” (10.17267/2675-021xevidence.v1i2.2625) | Abstract References ORCID | 0.00 | 0 |
| 77 | The yearly cost of formatting and why Evidence decided to fo… (10.17267/2675-021xevidence.v1i2.2725) | Abstract References | 0.00 | 0 |
| 78 | Masthead (10.17267/2675-021xevidence.v1i2.2749) | Abstract References ORCID | 0.00 | 0 |
| 79 | Markers of fluid responsiveness in hemodynamically unstable… (10.17267/2675-021xevidence.v2i1.2595) | Abstract References | 0.00 | 0 |
| 80 | Inhaled steroids for asthma after emergency department disch… (10.17267/2675-021xevidence.v2i1.2696) | Abstract References | 0.00 | 0 |
| 81 | Study publication date should not dictate suitability of met… (10.17267/2675-021xevidence.v2i1.2796) | Abstract References ORCID | 0.00 | 0 |
| 82 | Protocolo de estudo para avaliar programas de prevenção e co… (10.17267/2675-021xevidence.v2i1.2822) | References ORCID | 0.00 | 0 |
| 83 | Spin: modificações na redação científica que escondem fragil… (10.17267/2675-021xevidence.v2i1.2840) | Abstract References ORCID | 0.00 | 0 |
| 84 | A safety profile is sufficient for using a drug? (10.17267/2675-021xevidence.v2i1.2938) | Abstract References | 0.00 | 0 |
| 85 | Do in vitro ao in vivo: a eficácia da cloroquina no tratamen… (10.17267/2675-021xevidence.v2i1.2960) | Abstract References | 0.00 | 0 |
| 86 | Antiarrhythmics in patients with out-of-hospital-cardiac arr… (10.17267/2675-021xevidence.v2i1.3007) | Abstract References ORCID | 0.00 | 0 |
| 87 | Ensaios clínicos são mais difíceis de serem conduzidos em co… (10.17267/2675-021xevidence.v2i1.3010) | Abstract References ORCID | 0.00 | 0 |
| 88 | Glucocorticoid for croup in children (10.17267/2675-021xevidence.v2i1.3026) | Abstract References ORCID | 0.00 | 0 |
| 89 | Evidence-based health and the judicialization of health in B… (10.17267/2675-021xevidence.v2i1.3032) | Abstract References | 0.00 | 0 |
| 90 | A cloroquina e o paraquedas: uma fábula da era COVID19 (10.17267/2675-021xevidence.v2i1.3091) | References ORCID | 0.00 | 0 |
| 91 | Do pandemics justify non-evidence-based therapies? (10.17267/2675-021xevidence.v2i1.3125) | Abstract References ORCID | 0.00 | 0 |
| 92 | Masthead (10.17267/2675-021xevidence.v2i1.3267) | Abstract References ORCID | 0.00 | 0 |
| 93 | What is the evidence in favor of herd immunity for the COVID… (10.17267/2675-021xevidence.v2i2.3335) | Abstract References | 0.00 | 0 |
| 94 | Systemic Corticosteroids in COVID-19: Critical Appraisal of… (10.17267/2675-021xevidence.v2i2.3343) | Abstract References | 0.00 | 0 |
| 95 | A warning to readers about the term metanalysis in non-syste… (10.17267/2675-021xevidence.v2i2.3416) | References ORCID | 0.00 | 0 |
| 96 | Análise crítica de aspectos metodológicos e conceituais do "… (10.17267/2675-021xevidence.v2i2.3449) | Abstract References ORCID | 0.00 | 0 |
| 97 | Desmopressin for reducing perioperative blood transfusion (10.17267/2675-021xevidence.v2i2.3713) | Abstract References | 0.00 | 0 |
| 98 | Masthead (10.17267/2675-021xevidence.v2i2.3862) | Abstract References ORCID | 0.00 | 0 |